DDInter736 DDInter1658
Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or the need for surgical procedures.[L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss. Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo or in combination with [doxazosin], an alpha-blocker. Both benign prostatic hyperpl
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Finasteride {u} (Compound) resembles {v} (Compound) Dydrogesterone
Finasteride {u} (Compound) resembles {v} (Compound) Testosterone
Finasteride {u} (Compound) binds {v} (Gene) CYP3A7
Finasteride {u} (Compound) upregulates {v} (Gene) AGR2
Finasteride {u} (Compound) downregulates {v} (Gene) C2CD5
Finasteride {u} (Compound) causes {v} (Side Effect) Pharyngitis
Finasteride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Terazosin
Finasteride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somatrem
Finasteride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Finasteride (Compound) resembles Dydrogesterone (Compound)
Finasteride (Compound) resembles Testosterone (Compound)
Finasteride (Compound) binds CYP3A7 (Gene)
Finasteride (Compound) upregulates AGR2 (Gene)
Finasteride (Compound) downregulates C2CD5 (Gene)
Finasteride (Compound) causes Pharyngitis (Side Effect)
Finasteride may cause a minor interaction that can limit clinical effects when taken with Terazosin
Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus